Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2)
Phase 1/2TerminatedDevelopment Stage
Gynecologic Cancer
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Apr 4, 2022 → Aug 14, 2023
About Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2)
Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) is a phase 1/2 stage product being developed by Alaunos Therapeutics for Gynecologic Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05194735. Target conditions include Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Gynecologic Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05194735 | Phase 1/2 | Terminated |
Competing Products
13 competing products in Gynecologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 42 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 21 |
| Pembrolizumab | Merck | Phase 1 | 29 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 29 |
| Vigil + Atezolizumab | Roche | Phase 2 | 35 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 35 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 35 |
| AK112 | Akeso | Phase 2 | 35 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 40 |
| Floseal | Baxter | Phase 3 | 33 |
| FloSeal application | Baxter | Pre-clinical | 23 |
| IPH2201 | Innate Pharma | Phase 1 | 19 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 16 |